NYSEAMERICAN:CANF - CAN-FITE BIOPHA/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.29 +0.05 (+4.03 %)
(As of 07/20/2018 08:31 AM ET)
Previous Close$1.24
Today's Range$1.2216 - $1.29
52-Week Range$1.12 - $2.75
Volume51,669 shs
Average Volume191,578 shs
Market Capitalization$32.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94
CAN-FITE BIOPHA/S logoCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CANF
CUSIPN/A
Phone+972-3-9241114

Debt

Debt-to-Equity RatioN/A
Current Ratio7.29
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,453.03%
Return on Equity-57.94%
Return on Assets-32.52%

Miscellaneous

Employees7
Outstanding Shares19,980,000
Market Cap$32.28

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) Frequently Asked Questions

What is CAN-FITE BIOPHA/S's stock symbol?

CAN-FITE BIOPHA/S trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How were CAN-FITE BIOPHA/S's earnings last quarter?

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) released its quarterly earnings results on Friday, June, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $0.63 million during the quarter. CAN-FITE BIOPHA/S had a negative net margin of 2,453.03% and a negative return on equity of 57.94%. View CAN-FITE BIOPHA/S's Earnings History.

When is CAN-FITE BIOPHA/S's next earnings date?

CAN-FITE BIOPHA/S is scheduled to release their next quarterly earnings announcement on Friday, September, 7th 2018. View Earnings Estimates for CAN-FITE BIOPHA/S.

What price target have analysts set for CANF?

2 equities research analysts have issued 12 month price targets for CAN-FITE BIOPHA/S's shares. Their predictions range from $7.00 to $8.00. On average, they expect CAN-FITE BIOPHA/S's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 481.4% from the stock's current price. View Analyst Ratings for CAN-FITE BIOPHA/S.

What is the consensus analysts' recommendation for CAN-FITE BIOPHA/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CAN-FITE BIOPHA/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 302,241 shares, a drop of 14.1% from the June 15th total of 351,936 shares. Based on an average trading volume of 208,682 shares, the short-interest ratio is presently 1.4 days. View CAN-FITE BIOPHA/S's Current Options Chain.

Who are some of CAN-FITE BIOPHA/S's key competitors?

Who are CAN-FITE BIOPHA/S's key executives?

CAN-FITE BIOPHA/S's management team includes the folowing people:
  • Prof. Pnina Fishman Ph.D., Scientific Founder, Chief Exec. Officer & Director (Age 70)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)
  • Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 64)
  • Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical Director
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

Has CAN-FITE BIOPHA/S been receiving favorable news coverage?

News stories about CANF stock have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CAN-FITE BIOPHA/S earned a daily sentiment score of 0.24 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of CAN-FITE BIOPHA/S?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CAN-FITE BIOPHA/S's stock price today?

One share of CANF stock can currently be purchased for approximately $1.29.

How big of a company is CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S has a market capitalization of $32.28 million. CAN-FITE BIOPHA/S employs 7 workers across the globe.

How can I contact CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.


MarketBeat Community Rating for CAN-FITE BIOPHA/S (NYSEAMERICAN CANF)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about CAN-FITE BIOPHA/S and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.